A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

NCT02819882

Last updated date
Study Location
Althaia-Xarxa Assistencial de Manresa
Manresa, Barcelona, 08243, Spain
Contact
+34 916892870

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

+34 916892870

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016.

2. Able and willing to provide written informed consent.

3. Age ≥ 18 years.

4. Availability to medical records access and all data related to the disease management.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


None

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast NeoplasmsTumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
NCT04858997
  1. Hangzhou, Zhejiang
Female
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsA Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
NCT02819882
  1. Manresa, Barcelona
  2. Terrassa, Barcelona
  3. San Sebastián, Donostia
  4. Las Palmas de Gran Canaria, Gran Canaria
  5. Alcorcón, Madrid
  6. Fuenlabrada, Madrid
  7. Leganés, Madrid
  8. San Sebastián de los Reyes, Madrid
  9. Palma de Mallorca, Mallorca
  10. Pamplona, Navarra
  11. Santa Cruz de Tenerife, Tenerife
  12. Bilbao, Vizcaya
  13. A Coruña,
  14. Albacete,
  15. Alicante,
  16. Barcelona,
  17. Barcelona,
  18. Barcelona,
  19. Barcelona,
  20. Barcelona,
  21. Barcelona,
  22. Cáceres,
  23. Córdoba,
  24. León,
  25. Lugo,
  26. Madrid,
  27. Madrid,
  28. Murcia,
  29. Málaga,
  30. Salamanca,
  31. Sevilla,
  32. Toledo,
  33. Valencia,
  34. Valencia,
  35. Valencia,
  36. Valencia,
  37. Zaragoza,
  38. Zaragoza,
  39. Elche, Alicante
  40. Sagunto, Valencia
  41. Ávila,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Breast NeoplasmsEvaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer
NCT00242203
  1. St. Louis, Missouri
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Official Title A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Brief Summary This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Detailed Description

The target population for inclusion in this study is breast cancer patients recently diagnosed (from January 2016) with unresectable locally advanced or metastatic disease (either after a recurrence or as first diagnosis). No treatment regimen will be protocol specified. This is an observational study in which clinical decisions concerning the optimum management strategy for a particular patient are taken independently of and/or prior to, any decision by the physician to invite a patient to participate in the study. The treating physician will make all treatment decisions according to his/her regular clinical practice independent of this study. Patients enrolled on the study are free to withdraw their informed consent for the use and disclosure of health information at any time and when asked, patients are not obliged to provide a reason. Patients may request discontinuation from the study at any time.

The date and the reason for withdrawal or discontinuation from the study must be recorded in the electronic case report form (eCRF). An attempt will be made to determine the date of discontinuation and final status (i. e. withdrawal of consent, loss to follow-up, death) of any patient who discontinues from the study. However, the treating clinician is encouraged to follow the patient as long as possible, until patient death or through study end. The Sponsor has the right to terminate the study at any time. The Sponsor will notify the investigator if the study is placed on hold or if the Sponsor decides to discontinue the study.

Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 5 Years
Biospecimen Retention:   Samples With DNA
Description:
Blood samples Primary and metastatic lesion tissue samples
Sampling Method Non-Probability Sample
Study Population The target population for inclusion in this study is breast cancer patients recently diagnosed (from January 2016) with unresectable locally advanced or metastatic disease (either after a recurrence or as first diagnosis).
Condition Breast Neoplasms
Intervention Other: No intervention
Study Groups/Cohorts
  • Luminal A-like subtype
    Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (? 20%), don't express HER2 and have Ki-67 'low' (< 14%).
    Intervention: Other: No intervention
  • Luminal B-like (HER2 negative) subtype:
    Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (? 14%).
    Intervention: Other: No intervention
  • Luminal B-like (HER2 positive) subtype:
    Patients that express ER and HER2 irrespective of PgR or Ki67 status.
    Intervention: Other: No intervention
  • HER2-enriched subtype
    Patients that express HER2 and don't express ER or PgR.
    Intervention: Other: No intervention
  • Triple Negative (TN) subtype
    Patients who are negative for the expression of ER, PgR and HER2.
    Intervention: Other: No intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: June 27, 2016)
1400
Original Estimated Enrollment Same as current
Estimated Study Completion Date June 2024
Estimated Primary Completion Date June 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  1. Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016.
  2. Able and willing to provide written informed consent.
  3. Age ? 18 years.
  4. Availability to medical records access and all data related to the disease management.

Exclusion Criteria:

None

Sex/Gender
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: MS Study Project Manager+34 916892870[email protected]
Contact: Start-Up Unit Manager+34 916892870[email protected]
Listed Location Countries Spain
Removed Location Countries  
 
Administrative Information
NCT Number NCT02819882
Other Study ID Numbers GEICAM 2014-03
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Responsible Party Spanish Breast Cancer Research Group
Study Sponsor Spanish Breast Cancer Research Group
Collaborators
  • Hoffmann-La Roche
  • Novartis
  • AstraZeneca
  • Pfizer
  • Celgene
Investigators
Study Director:Study DirectorHospital Universitario Fundación Alcorcón, Madrid
Study Director:Study DirectorHospital de Donostia, San Sebastián
Study Director:Study DirectorHospital Universitario Gregorio Marañón, Madrid
Study Director:Study DirectorHospital Universitario Reina Sofía,Córdoba
PRS Account Spanish Breast Cancer Research Group
Verification Date December 2020